Pam Belluck

Pam Belluck

@PamBelluck

Followers9.8K
Following993

New York Times writer covering health & science. Author of "Island Practice," a book about a quirky island doctor. Jazz flutist. Lapsed Ultimate Frisbee player.

Joined on December 07, 2009
@PamBelluck Statistics

We looked inside some of the tweets by @PamBelluck and found useful information for you.

Inside 100 Tweets

Time between tweets:
9 hours
Average replies
14
Average retweets
50
Average likes
211
Tweets with photos
21 / 100
Tweets with videos
0 / 100
Tweets with links
0 / 100
Fun Fact

The average Twitter user has 126 followers.

Post-covid patients may experience new medical problems

Analysis of almost 2m #patients found issues for nearly 25% them — including those who had a mild or asymptomatic #infection

cc ➤ @RWalensky @VirusesImmunity @PaulSaxMD

https://t.co/cBqPwE6hyH ht @PamBelluck @nytimes https://t.co/Ydynkb2G8Y

Post-covid patients may experience new medical problems Analysis of almost 2m #patients found issues for nearly 25% them — including those who had a mild or asymptomatic #infection cc ➤ @RWalensky @VirusesImmunity @PaulSaxMD https://t.co/cBqPwE6hyH ht @PamBelluck @nytimes https://t.co/Ydynkb2G8Y

Las secuelas del coronavirus podrían incluir afecciones nuevas para los pacientes https://t.co/k7oP8RwC6A

0
0
0

It's not peer-reviewed, and has some other caveats, but study shows that many post-#Covid patients are experiencing new and wide-ranging medical problems by @PamBelluck https://t.co/rDfsBlmFiT #COVID19 #LongCovid #longhaulers

2
2
2
From the large insurer report of >1.9 million people with covid, a large proportion were asymptomatic and nearly 1 in 5 of them had symptoms 1-month post covid diagnosis
https://t.co/NPTqGn4hYX
https://t.co/4rJEX7sKEQ by @PamBelluck https://t.co/DJh7u6MgZ7
2

From the large insurer report of >1.9 million people with covid, a large proportion were asymptomatic and nearly 1 in 5 of them had symptoms 1-month post covid diagnosis https://t.co/NPTqGn4hYX https://t.co/4rJEX7sKEQ by @PamBelluck https://t.co/DJh7u6MgZ7

From an insurance claims report of #LongCOVID … 'Of patients who had COVID-19, 23.2% had at least one post-COVID condition.’ Reported by @PamBelluck @nytimes https://t.co/rsK8QZBcM9 https://t.co/coCt61stdu https://t.co/PppiJAFPLx

From an insurance claims report of #LongCOVID … 'Of patients who had COVID-19, 23.2% had at least one post-COVID condition.’ Reported by @PamBelluck @nytimes https://t.co/rsK8QZBcM9 https://t.co/coCt61stdu https://t.co/PppiJAFPLx

Still, it seems to be the largest so far looking at post-Covid health issues. It underscores, says @zalaly, that "people with long Covid need multidisciplinary care and our health systems should adapt to this reality and develop capacity to deal with these patients."3/3

1
4
11

The study has limitations, including: it only uses private health insurance records, no control group to allow comparison to people who didn't have Covid, no data on when symptoms arose or how long problems persisted, diagnostic codes can miss or miscategorize symptoms. 2/3

1
0
3

Large new study on post-Covid health: 23 percent of nearly 2 million coronavirus patients sought medical care for new health problems one month or more after getting Covid-19. 1/3 https://t.co/5MOAR0A0Bf

2
16
20

As the pandemic eases, the F.D.A. is trying to catch up on inspections, reviews of cell and gene therapies, and other work delayed due to Covid.  https://t.co/yx3g5QhMXF

1
2
2

In approving Biogen's controversial Alzheimer's drug this week, the F.D.A. overruled the objections of its independent advisers. Now, three of those advisers have resigned. https://t.co/RqldSLhPFY

0
14
11

Quoted @ellenlebowitz

Read this story about the the new drug for Alzheimer's, and, every other story @Pam Belluck writes. Her research and writing are both remarkable. https://t.co/I1j6mJje9Q

Thank you so much! I really appreciate this very kind comment! https://t.co/Umvh0DhLhb

0
0
2

Want to understand what's going on with the new Alzheimer's drug? Listen to ⁦@PamBelluck⁩ here https://t.co/21tXdcxNoj

0
1
5

Quoted @nytimes

The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. https://t.co/ghMdQs0W4J https://t.co/2HfAc7E48S

The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. https://t.co/ghMdQs0W4J https://t.co/2HfAc7E48S

what a public service it was and still is incredibly proud of this newsroom https://t.co/vGKIvlGtdg

Quoted @scifri

This week, the FDA approved the new Alzheimer's drug aducanumab, but it’s unclear if the costly treatment actually leads to improved cognition and memory in people with the disease. @NYtimes's reporter @PamBelluck shares more on #SciFriLive📻. https://t.co/v8ILc5Er9x

Enjoyed talking with @johndankosky on @scifri about the controversial approval of the new drug for Alzheimer's disease https://t.co/RgvTwXpSsF

0
3
8

Quoted @fredguterl

Huge congrats to @apoorva_nyc @carlzimmer @PamBelluck and the rest of the NYT covid team. Also: thanks https://t.co/YnEljnx8zU

Thank you! Honored to contribute to the NYT's Covid coverage with my wonderful colleagues! https://t.co/vlRa93ZgVx

1
1
4
The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. https://t.co/ghMdQs0W4J https://t.co/2HfAc7E48S

The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. https://t.co/ghMdQs0W4J https://t.co/2HfAc7E48S

235
776
4K

In approving Biogen's controversial Alzheimer's drug this week, the F.D.A. overruled the objections of its independent advisers. Now, three of those advisers have resigned. https://t.co/TUZzl72VDD

1
10
7
Ash Paul
10 days ago

Three @US_FDA Advisers Resign Over Agency’s Approval of Alzheimer’s Drug: The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients. https://t.co/n7s3nQ3cCG via @PamBelluck & @RebeccaDRobbins

5
15
23

The FDA's approval of $BIIB's Aduhelm is spurring major backlash in the scientific community — most notably, with the resignations of 3 advisers to the agency. The question now is whether lawmakers, payers and patients will balk. With @PamBelluck: https://t.co/DSzzLiNBtG

10
44
82
Next Page